持续静滴顺铂与口服依托泊甙治疗晚期非小细胞肺癌的临床观察

doi:10.3971/j.issn.1000-8578.338

持续静滴顺铂与口服依托泊甙治疗晚期非小细胞肺癌的临床观察

Clinical Observations of Advanced Non-Small-Cell Lung Cancer Patients Treated with Continuous Infusion of Cisplatin and Oral Etoposide

摘要

摘要: 目的　探讨持续静滴顺铂与口服依托泊甙(VP-16)治疗非小细胞肺癌(NSCLC)。方法　61例晚期NSCLC随机分为治疗组(33例)、对照组(28例)。对照组予常规EP方案。治疗组予顺铂20mg/m2/日持续静滴4天及VP-16胶囊50mg Bid×10天。结果　有效率(CR+PR)治疗组(57.6%)高于对照组(32.1%，P<0.05)；治疗组消化道反应及肾毒性小，生活质量改善明显(P<0.05)。结论　持续静滴顺铂与口服VP-16胶囊为晚期NSCLC有效、安全的治疗方案。

Abstract: Objective To study the efficacy of continuous infusion of cisplatin and oral etoposide in the treatment of non-small-cell lung cancer (NSCLC). Methods 61 cases with NSCLC(stage Ⅲ-Ⅳ)were randomized into treated group(TG,33 cases)and control group(CG,28 cases).CG was treated with conventional EP regimen.TG was treated with cisplatin (20mg/m2 daily for 4 days by i.v. continuous infusion)and etoposide capsules(50mg orally,twice daily for 10 days). Results The response rate (CR+PR) of TG(57.6%) was significantly higher than that of CG(32.1%，P<0.05).The incidence of nausea and emesis in TG(15.1%)was significantly lower than that in CG(46.4%，P<0.01).Kidney disfunction occurred less in TG. The quality of life in TG was improved better than that in CG(P<0.05). Conclusion The efficacy of continuous infusion of cisplatin and oral etoposide in the treatment of advanced NSCLC was better than that of conventional EP regimen.There were less side effects in the regimen.It was on effective,safe treatment for advanced NSCLC.

HTML全文

参考文献(0)

施引文献

资源附件(0)